Clinical Trial Update: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma [Phase 2]

View source ↗

Summary

An update on a Phase 2 study evaluating adverse events of subcutaneous epcoritamab in adults with relapsed or refractory diffuse large B-cell lymphoma and class…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING